Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1081 to 1085 of 1085 entries
Sorted by: Best Match Show Resources per page
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.

European journal of cancer (Oxford, England : 1990)

Stouvenot M, Meurisse A, Saint A, Buecher B, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Smith D, Ghiringhelli F, Parzy A, de la Fouchardiere C, Almotlak H, Vienot A, Jacquin M, Taieb J, Nguyen T, Vernerey D, Borg C, Kim S.
PMID: 34995900
Eur J Cancer. 2022 Jan 04;162:138-147. doi: 10.1016/j.ejca.2021.11.019. Epub 2022 Jan 04.

BACKGROUND: Squamous cell carcinoma of the anus (SCCA) is a rare disease often diagnosed at a localised stage. For locally advanced recurrence or metastatic disease, DCF (docetaxel, cisplatin, 5-fluorouracil) demonstrated high efficacy and became one of the standard regimens....

Cite
Stouvenot M, Meurisse A, Saint A, et al. Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies. Eur J Cancer. 2022;162:138-147doi: 10.1016/j.ejca.2021.11.019.
Stouvenot, M., Meurisse, A., Saint, A., Buecher, B., André, T., Samalin, E., Jary, M., El Hajbi, F., Baba-Hamed, N., Pernot, S., Kaminsky, M. C., Bouché, O., Desrame, J., Zoubir, M., Smith, D., Ghiringhelli, F., Parzy, A., de la Fouchardiere, C., Almotlak, H., Vienot, A., Jacquin, M., Taieb, J., Nguyen, T., Vernerey, D., Borg, C., & Kim, S. (2022). Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies. European journal of cancer (Oxford, England : 1990), 162138-147. https://doi.org/10.1016/j.ejca.2021.11.019
Stouvenot, Morgane, et al. "Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies." European journal of cancer (Oxford, England : 1990) vol. 162 (2022): 138-147. doi: https://doi.org/10.1016/j.ejca.2021.11.019
Stouvenot M, Meurisse A, Saint A, Buecher B, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Smith D, Ghiringhelli F, Parzy A, de la Fouchardiere C, Almotlak H, Vienot A, Jacquin M, Taieb J, Nguyen T, Vernerey D, Borg C, Kim S. Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies. Eur J Cancer. 2022 Jan 04;162:138-147. doi: 10.1016/j.ejca.2021.11.019. Epub 2022 Jan 04. PMID: 34995900.
Copy Download .nbib Format: NLM
Atezolizumab-induced autoimmune haemolytic anaemia caused by drug-independent antibodies.

European journal of cancer (Oxford, England : 1990)

Chambers BS, Ward D, Webster R, Tunnard V, Hill QA.
PMID: 34998047
Eur J Cancer. 2022 Jan 05;162:158-160. doi: 10.1016/j.ejca.2021.11.031. Epub 2022 Jan 05.

No abstract available.

Cite
Chambers BS, Ward D, Webster R, et al. Atezolizumab-induced autoimmune haemolytic anaemia caused by drug-independent antibodies. Eur J Cancer. 2022;162:158-160doi: 10.1016/j.ejca.2021.11.031.
Chambers, B. S., Ward, D., Webster, R., Tunnard, V., & Hill, Q. A. (2022). Atezolizumab-induced autoimmune haemolytic anaemia caused by drug-independent antibodies. European journal of cancer (Oxford, England : 1990), 162158-160. https://doi.org/10.1016/j.ejca.2021.11.031
Chambers, Bradley S, et al. "Atezolizumab-induced autoimmune haemolytic anaemia caused by drug-independent antibodies." European journal of cancer (Oxford, England : 1990) vol. 162 (2022): 158-160. doi: https://doi.org/10.1016/j.ejca.2021.11.031
Chambers BS, Ward D, Webster R, Tunnard V, Hill QA. Atezolizumab-induced autoimmune haemolytic anaemia caused by drug-independent antibodies. Eur J Cancer. 2022 Jan 05;162:158-160. doi: 10.1016/j.ejca.2021.11.031. Epub 2022 Jan 05. PMID: 34998047.
Copy Download .nbib Format: NLM
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.

European journal of cancer (Oxford, England : 1990)

Hulshof EC, de With M, de Man FM, Creemers GJ, Deiman BALM, Swen JJ, Houterman S, Koolen SLW, Bins S, Thijs AMJ, Laven MMJ, Hövels AM, Luelmo SAC, Houtsma D, Shulman K, McLeod HL, van Schaik RHN, Guchelaar HJ, Mathijssen RHJ, Gelderblom H, Deenen MJ.
PMID: 34998046
Eur J Cancer. 2022 Jan 05;162:148-157. doi: 10.1016/j.ejca.2021.12.009. Epub 2022 Jan 05.

AIM: To determine the safety, feasibility, pharmacokinetics, and cost of UGT1A1 genotype-guided dosing of irinotecan.PATIENTS AND METHODS: In this prospective, multicentre, non-randomised study, patients intended for treatment with irinotecan were pre-therapeutically genotyped for UGT1A1∗28 and UGT1A1∗93. Homozygous variant carriers...

Cite
Hulshof EC, de With M, de Man FM, et al. UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. Eur J Cancer. 2022;162:148-157doi: 10.1016/j.ejca.2021.12.009.
Hulshof, E. C., de With, M., de Man, F. M., Creemers, G. J., Deiman, B. A. L. M., Swen, J. J., Houterman, S., Koolen, S. L. W., Bins, S., Thijs, A. M. J., Laven, M. M. J., Hövels, A. M., Luelmo, S. A. C., Houtsma, D., Shulman, K., McLeod, H. L., van Schaik, R. H. N., Guchelaar, H. J., Mathijssen, R. H. J., Gelderblom, H., & Deenen, M. J. (2022). UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. European journal of cancer (Oxford, England : 1990), 162148-157. https://doi.org/10.1016/j.ejca.2021.12.009
Hulshof, Emma C, et al. "UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients." European journal of cancer (Oxford, England : 1990) vol. 162 (2022): 148-157. doi: https://doi.org/10.1016/j.ejca.2021.12.009
Hulshof EC, de With M, de Man FM, Creemers GJ, Deiman BALM, Swen JJ, Houterman S, Koolen SLW, Bins S, Thijs AMJ, Laven MMJ, Hövels AM, Luelmo SAC, Houtsma D, Shulman K, McLeod HL, van Schaik RHN, Guchelaar HJ, Mathijssen RHJ, Gelderblom H, Deenen MJ. UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. Eur J Cancer. 2022 Jan 05;162:148-157. doi: 10.1016/j.ejca.2021.12.009. Epub 2022 Jan 05. PMID: 34998046.
Copy Download .nbib Format: NLM
Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years.

European journal of cancer (Oxford, England : 1990)

Steindl A, Brunner TJ, Heimbach K, Schweighart K, Moser GM, Niziolek HM, Moor E, Kreminger J, Starzer AM, Dieckmann K, Gatterbauer B, Widhalm G, Preusser M, Berghoff AS.
PMID: 34998049
Eur J Cancer. 2022 Jan 05;162:170-181. doi: 10.1016/j.ejca.2021.12.005. Epub 2022 Jan 05.

BACKGROUND: An accurate classification of patients with brain metastases (BMs) is an important foundation to guide individualised treatment decisions and to formulate BM cohorts for modern clinical trials.METHODS: Six thousand and thirty-one patients with newly diagnosed BM from different...

Cite
Steindl A, Brunner TJ, Heimbach K, et al. Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years. Eur J Cancer. 2022;162:170-181doi: 10.1016/j.ejca.2021.12.005.
Steindl, A., Brunner, T. J., Heimbach, K., Schweighart, K., Moser, G. M., Niziolek, H. M., Moor, E., Kreminger, J., Starzer, A. M., Dieckmann, K., Gatterbauer, B., Widhalm, G., Preusser, M., & Berghoff, A. S. (2022). Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years. European journal of cancer (Oxford, England : 1990), 162170-181. https://doi.org/10.1016/j.ejca.2021.12.005
Steindl, Ariane, et al. "Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years." European journal of cancer (Oxford, England : 1990) vol. 162 (2022): 170-181. doi: https://doi.org/10.1016/j.ejca.2021.12.005
Steindl A, Brunner TJ, Heimbach K, Schweighart K, Moser GM, Niziolek HM, Moor E, Kreminger J, Starzer AM, Dieckmann K, Gatterbauer B, Widhalm G, Preusser M, Berghoff AS. Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years. Eur J Cancer. 2022 Jan 05;162:170-181. doi: 10.1016/j.ejca.2021.12.005. Epub 2022 Jan 05. PMID: 34998049.
Copy Download .nbib Format: NLM
PD-1 inhibitors in patients with Hodgkin lymphoma.

European journal of cancer (Oxford, England : 1990)

Rossi C, Casasnovas RO.
PMID: 34456113
Eur J Cancer. 2021 Aug 26; doi: 10.1016/j.ejca.2021.06.059. Epub 2021 Aug 26.

No abstract available.

Cite
Rossi C, Casasnovas RO. PD-1 inhibitors in patients with Hodgkin lymphoma. Eur J Cancer. 2021;doi: 10.1016/j.ejca.2021.06.059.
Rossi, C., & Casasnovas, R. O. (2021). PD-1 inhibitors in patients with Hodgkin lymphoma. European journal of cancer (Oxford, England : 1990), . https://doi.org/10.1016/j.ejca.2021.06.059
Rossi, Cédric, and Casasnovas, René-Olivier. "PD-1 inhibitors in patients with Hodgkin lymphoma." European journal of cancer (Oxford, England : 1990) vol. (2021). doi: https://doi.org/10.1016/j.ejca.2021.06.059
Rossi C, Casasnovas RO. PD-1 inhibitors in patients with Hodgkin lymphoma. Eur J Cancer. 2021 Aug 26; doi: 10.1016/j.ejca.2021.06.059. Epub 2021 Aug 26. PMID: 34456113.
Copy Download .nbib Format: NLM
Showing 1081 to 1085 of 1085 entries